Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03467789 · ClinicalTrials.gov registry record · Phase 1

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

A Phase 1 study, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target

NCT03467789 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 37 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03467789, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target

Study Summary

The purpose of this study is to study 50 patients with multiple Basal Cell Carcinoma (BCC) who will be receiving Photodynamic Therapy (PDT) as treatment for their tumors. This study wants to establish the optimal conditions for treating BCC tumors with PDT. Previous research suggests that taking Vitamin D prior to the start of PDT could help improve the effectiveness of the treatment in eliminating the BCC. Overall, this study will help establish oral Vitamin D3/PDT as a new combination therapy for skin cancer (BCC). Photodynamic Therapy (PDT) is an investigational (experimental) technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells. PDT is currently approved for the treatment of BCC in Europe, Canada, and Australia. However, it is experimental in the United States because it is not approved by the Food and Drug Administration (FDA).

Interventions

  • DRUG Dietary Vitamin D3 pre-treatment
  • RADIATION Photodynamic therapy
  • DRUG Serum Maintenance Vitamin D3

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2018-10-01
Est. Completion 2023-01-06
Phase Phase 1

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT03467789

The ClinicalTrials.gov registry entry for NCT03467789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Dietary Vitamin D3 pre-treatment is the first listed.

NCT03467789 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03467789 about?

NCT03467789 is a clinical study titled "Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma". The purpose of this study is to study 50 patients with multiple Basal Cell Carcinoma (BCC) who will be receiving Photodynamic Therapy (PDT) as treatment for their tumors. This study wants to establish the optimal conditions for treating BCC tumors with PDT. Previous research suggests that taking Vit...

What is the current status of trial NCT03467789?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-10-01. Estimated completion is 2023-01-06.

What interventions are being tested in trial NCT03467789?

The interventions under investigation include: Dietary Vitamin D3 pre-treatment (DRUG), Photodynamic therapy (RADIATION), Serum Maintenance Vitamin D3 (DRUG).

Who is sponsoring clinical trial NCT03467789?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.